Our top pick for
NantHealth, Inc is a health information services business based in the US. NantHealth shares (NH) are listed on the NASDAQ and all prices are listed in US Dollars. NantHealth employs 398 staff and has a trailing 12-month revenue of around USD$91.6 million.
Since the stock market crash in March caused by coronavirus, NantHealth's share price has had significant positive movement.
Its last market close was USD$2.19, which is 13.24% up on its pre-crash value of USD$1.9 and 99.09% up on the lowest point reached during the March crash when the shares fell as low as USD$1.1.
If you had bought USD$1,000 worth of NantHealth shares at the start of February 2020, those shares would have been worth USD$780.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,335.37.
|Latest market close||USD$2.19|
|52-week range||USD$0.811 - USD$6.39|
|50-day moving average||USD$2.2574|
|200-day moving average||USD$3.1628|
|Wall St. target price||USD$3.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.651|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||8.96%|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Revenue TTM||USD$91.6 million|
|Gross profit TTM||USD$62.2 million|
|Return on assets TTM||-5.72%|
|Return on equity TTM||0%|
|Market capitalisation||USD$261.3 million|
TTM: trailing 12 months
There are currently 1.5 million NantHealth shares held short by investors – that's known as NantHealth's "short interest". This figure is 2.3% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting NantHealth shares can be evaluated.
NantHealth's "short interest ratio" (SIR) is the quantity of NantHealth shares currently shorted divided by the average quantity of NantHealth shares traded daily (recently around 182773.75296912). NantHealth's SIR currently stands at 8.42. In other words for every 100,000 NantHealth shares traded daily on the market, roughly 8420 shares are currently held short.
However NantHealth's short interest can also be evaluated against the total number of NantHealth shares, or, against the total number of tradable NantHealth shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NantHealth's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 NantHealth shares in existence, roughly 10 shares are currently held short) or 0.0561% of the tradable shares (for every 100,000 tradable NantHealth shares, roughly 56 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NantHealth.
Find out more about how you can short NantHealth stock.
We're not expecting NantHealth to pay a dividend over the next 12 months.
Over the last 12 months, NantHealth's shares have ranged in value from as little as $0.811 up to $6.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantHealth's is 1.7917. This would suggest that NantHealth's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company converging science and technology in the United States, the United Kingdom, Singapore, and Canada. It provides NantHealth solutions, including molecular profiling solutions, software-as-a-service platforms, and connected care medical device interoperability solutions to enable value-based care and evidence-based clinical practice. The company's products include GPS Cancer, a molecular profile that integrates whole genome/exome sequencing of tumor and normal germline samples, as well as whole transcriptome sequencing; GPS Cancer Report, a GPS cancer solution; Liquid GPS, a blood-based molecular laboratory test that provides a tool for noninvasive tumor profiling and quantitative monitoring of treatment response; and Eviti, a decision support solution that provides evidence-based clinical decision support. It also offers web-based and mobile software solutions, such as Device Connectivity Suite, a device connectivity and near real-time biometric software and hardware suite to aggregate data from in-hospital and remote medical devices. In addition, NantHealth, Inc. provides NaviNet Open, a payer-provider collaboration platform comprising plan central, eligibility and benefit, claims status inquiry, claims management, referral, authorization, and document exchange, as well as AllPayer Access services; and systems infrastructure solutions, which include cloud computing, storage, and transport infrastructure. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was founded in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.